Shinya H. Kimura
Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Shinya H. Kimura

Saga, JP 
Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Saga, JP 
OverviewLocationsClinical Research

Overview

Shinya Kimura practices in Saga, Japan. Mr. Kimura is rated as an Experienced expert by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 335 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Gender
Male

Locations

Saga, Japan
Other Locations
Wako, 3510198, Japan
Kiyose, Japan
Nishinomiya-hama, 6638501, Japan
Nagakute, Japan
Nabeshima, 8498501, Japan
Tokyo, Japan
Hatanodai, 1428666, Japan
Kariya, Japan
Chiba, Japan
Noda, 2788510, Japan
Koganei, 1848588, Japan
Tsukuba, 3058577, Japan
Minato, Japan
St. Marianna University School of Medicine
Kawasaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

335 Total Publications

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.
Journal: Expert review of hematology
Published: January 07, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kimura's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 91 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile